News | Venous Therapies | November 22, 2021

Early Thrombosis After Iliac Stenting for Venous Outflow Occlusion Is Related to Disease Severity and Type of Anticoagulation

Courtesy Getty Images

November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral venous occlusion prior to transition to oral anticoagulation reduces early thrombosis, according to a multi-center study.

Thrombosis following iliofemoral venous stenting is frustrating to both the patient and clinician and is an understudied phenomenon, according to a study in the November issue of the Journal of Vascular Surgery: Venous and Lymphatic Disorders.1

“Most reported data describing stent occlusion after venous intervention have included patients across the full spectrum of venous disease. Including patients with non-thrombotic disease and limited anatomic involvement as well as patients with more extensive disease has prevented the identification of specific variables relating to the outcomes for either group of patients separately,” said principal investigator William Marston, M.D., from the University of North Carolina.

“In this study, we investigated a patient cohort with venous outflow occlusion requiring recanalization before stenting to determine the outcomes after intervention. We focused on the variables associated with early stent thrombosis in this high-risk segment of patients presenting with iliocaval outflow obstruction,” he continued.

Marston’s team retrospectively studied patients undergoing iliofemoral venous stenting at their institution (11 practitioners, two hospitals) from 2010 to 2020.

Only patients with type III (single segment) and type IV (multiple segment) iliofemoral venous occlusions were included.

A total of 106 patients were studied and had the following characteristics:

  • Age 50 +/- 14 years

  • Type III (41%) versus type IV (59%) disease pattern

  • One fourth with known hypercoagulable state

Treatment included:

  • Mean stent length 177 +/- 63mm

  • Antiplatelet therapy in 53%

  • Anticoagulation in 95%

  • Anticoagulation involving LMWH

    - As a bridge (<10 days) to warfarin (n=9), or

    - For two to four weeks before transition to oral anticoagulation (n=41)

  • Anticoagulation with a DOAC (n=39)

Three months following the procedure, occlusion of the stented region occurred in 26%. The observed three-year patency rates were primary, 59%, and secondary, 76%.

Risk factors for early (within three months) stent thrombosis were:

  • Type IV disease (odds ratio 4.6)

  • Hypercoaguable state (odds ratio 3.8)

  • Treatment with LMWH for >10 days was associated with lower odds (0.01) of early thrombosis.

“Patients with more extensive disease (type IV) experienced a greater incidence of thrombosis,” Marston said. “Therefore, studies that group non-thrombotic with post-thrombotic patients who have undergone stenting will be less able to identify the best treatment protocols.

“No consensus has been reached regarding the optimal postoperative anticoagulation therapy for these patients. Our study suggests that extended use of LMWH reduces early thrombosis.”

About the Society for Vascular Surgery

The Society for Vascular Surgery is the leading not-for-profit, professional medical society on establishing causes and treatments for vascular disease. SVS seeks to advance excellence and innovation in vascular health through education, advocacy, research and public awareness and is composed of specialty-trained vascular surgeons who are dedicated to providing comprehensive care for vascular disease. For more information visit


1 William A. Marston, Sydney E. Browder, Kathleen Iles, Anna Griffith, Katharine L. McGinigle. Early thrombosis after iliac stenting for venous outflow occlusion is related to disease severity and type of anticoagulation. Journal of Vascular Surgery: Venous and Lymphatic Disorders Published March 2, 2021. DOI:


Related Content

News | Cath Lab

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

Home December 20, 2023
News | Cath Lab

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

Home October 26, 2023
News | Cath Lab

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

Home October 25, 2023
News | Cath Lab

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

Home October 20, 2023
News | Cath Lab

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

Home October 16, 2023
News | Cath Lab

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

Home October 16, 2023
News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
News | Cath Lab

July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid ...

Home July 13, 2023
News | Cath Lab

June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake ...

Home June 21, 2023
Subscribe Now